Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII.

Naruto ShimonishiKeiji NogamiKenichi OgiwaraTomoko MatsumotoFumie NakazawaTetsuhiro SoedaMichinori HirataNobuo AraiMidori Shima

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2020)

Emicizumab effectively improved fibrin clot stability and structure in FVIII-deficient plasma, and the physical properties of emicizumab-induced fibrin clots were similar to those with FVIII.

Keyphrases

platelet rich plasma
high glucose
physical activity
mental health
endothelial cells
wild type